Cargando…

Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics

The relative bioavailability of lanabecestat administered as 2 tablet formulations versus an oral solution was investigated. This phase 1 single‐center, open‐label, randomized, 3‐period crossover study involved healthy male and nonfertile female subjects aged 18–55 years (NCT02039180). Subjects rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Naidong, Monk, Scott A., Daga, Pankaj, Bender, David M., Rosen, Laura B., Mullen, Jamie, Minkwitz, Margaret C., Kugler, Alan R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947295/ https://www.ncbi.nlm.nih.gov/pubmed/29319935 http://dx.doi.org/10.1002/cpdd.422

Ejemplares similares

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics
por: Eketjäll, Susanna, et al.
Publicado: (2016)

Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease
por: Hassan, Mubashir, et al.
Publicado: (2018)

Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease
por: Zimmer, Jennifer A., et al.
Publicado: (2021)

Effects of Tablet Formulation, Food, or Gastric pH on the Bioavailability of Asundexian
por: Kanefendt, Friederike, et al.
Publicado: (2022)

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials
por: Wessels, Alette M., et al.
Publicado: (2020)

3293 Region Specific Dysregulation of Dopaminergic Signaling in Mice Displaying Excessive Over-Grooming
por: Foster, Daniel, et al.
Publicado: (2019)

Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet
por: Badawi, Mohamed, et al.
Publicado: (2022)

The participation rate of migrant women in gestational diabetes screening in Austria: a retrospective analysis of 3293 births
por: Weiss, Christoph, et al.
Publicado: (2018)

Formulation Development of Albendazole-Loaded Self-Microemulsifying Chewable Tablets to Enhance Dissolution and Bioavailability
por: Sawatdee, Somchai, et al.
Publicado: (2019)

Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
por: Johnson, Mark, et al.
Publicado: (2022)

Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability
por: Ericsson, Hans, et al.
Publicado: (2019)

Formulation and evaluation of floating matrix tablet of stavudine
por: Prajapati, Pankaj H, et al.
Publicado: (2012)

Engineering of solidified glyburide nanocrystals for tablet formulation via loading of carriers: downstream processing, characterization, and bioavailability
por: Ali, Hany S M, et al.
Publicado: (2019)

Relative Bioavailability of Orally Dispersible Tablet Formulations of Levo‐ and Racemic Praziquantel: Two Phase I Studies
por: Bagchus, Wilhelmina Maria, et al.
Publicado: (2018)

Formulation of Aceclofenac Tablets Using Nanosuspension as Granulating Agent: An Attempt to Enhance Dissolution Rate and Oral Bioavailability
por: Rahim, Haroon, et al.
Publicado: (2020)

Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
por: Scheidel, Bernhard, et al.
Publicado: (2017)

Formulation, release characteristics, and bioavailability study of gastroretentive floating matrix tablet and floating raft system of Mebeverine HCl
por: El Nabarawi, Mohamed A, et al.
Publicado: (2017)

Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization
por: M. Tawfeek, Hesham, et al.
Publicado: (2020)

Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator’s product
por: Minzi, Omary MS, et al.
Publicado: (2013)

Development of Abiraterone Acetate Nanocrystal Tablets to Enhance Oral Bioavailability: Formulation Optimization, Characterization, In Vitro Dissolution and Pharmacokinetic Evaluation
por: Liu, Yuanfen, et al.
Publicado: (2022)

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK
por: Dean, Emma, et al.
Publicado: (2018)

Tablet Formulations of Polymeric Electrospun Fibers for the Controlled Release of Drugs with pH-Dependent Solubility
por: Friuli, Valeria, et al.
Publicado: (2022)

Dose-Dependent Bioavailability and Tissue Distribution of the ATR Inhibitor AZD6738 (ceralasertib) in Mice
por: Kiesel, Brian F., et al.
Publicado: (2022)

In vivo bioavailability studies of sumatriptan succinate buccal tablets
por: Shivanand, K, et al.
Publicado: (2011)

Relative bioavailability of ertugliflozin tablets containing the amorphous form versus tablets containing the cocrystal form
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2022)

Oral Bioavailability and Pharmacokinetics of Sildenafil Orally Disintegrating Tablets under Various Gastric pH Levels Following Administration of Omeprazole in Rats
por: Shih, Chin-Yu, et al.
Publicado: (2023)

Comparison of Bioavailability and Bioequivalence of Generic and Brand Name Formulations of Escitalopram Oxalate Tablets in Healthy Chinese Population Under Fasting and Fed Conditions
por: Li, Qiuying, et al.
Publicado: (2020)

Relative bioavailability of a pediatric dispersible tablet and adult film‐coated tablet of macitentan in healthy volunteers
por: Sidharta, Patricia N., et al.
Publicado: (2020)

Formulation and characterization of orodispersible tablet of glimepiride
por: Kinani, Ahmad AB Yosef, et al.
Publicado: (2022)

Enhancing Dissolution and Oral Bioavailability of Ursodeoxycholic Acid with a Spray-Dried pH-Modified Extended Release Formulation
por: Lee, Jaehyeok, et al.
Publicado: (2022)

Comparative Bioavailability and Tolerability of Single and Multiple Doses of 2 Diclofenac Sodium Sustained-Release Tablet Formulations in Fasting, Healthy Chinese Male Volunteers()
por: Zhai, Xue-Jia, et al.
Publicado: (2013)

Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability
por: Dennison, Thomas J, et al.
Publicado: (2017)

Bioavailability Study of an Innovative Orobuccal Formulation of Glutathione
por: Buonocore, Daniela, et al.
Publicado: (2016)

Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update
por: Lin, Yiping, et al.
Publicado: (2021)

Nanotechnology-based formulations to amplify intraocular bioavailability
por: Kagkelaris, Konstantinos, et al.
Publicado: (2022)

Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children
por: Svensson, Elin M., et al.
Publicado: (2018)

Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low‐ and High‐Mineral‐Content Water on the Tablet in Healthy Adults
por: Buchanan, Ann M., et al.
Publicado: (2017)

Spectrophotometric estimation of betahistine hydrochloride in tablet formulations
por: Kumar, Amit, et al.
Publicado: (2010)

Formulation and Evaluation of Omeprazole Tablets for Duodenal Ulcer
por: Choudhury, A., et al.
Publicado: (2010)

Formulation and Evaluation of Mouth Dissolving Tablets of Cinnarizine
por: Patel, B. P., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_muromp8gdte7c3p32keuo08h6r